{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:46:15Z","timestamp":1792784775319,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CVIR Endovasc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate artery embolization (PAE) has emerged as a minimally invasive therapy which affords improvement in benign prostatic hyperplasia (BPH) symptoms and objective urinary parameters with a favorable adverse event (AE) profile. While PAE was recently included in the American Urological Association (AUA) Guidelines, guidance on its specific use-cases is limited. This study sought to answer remaining questions surrounding the safety and efficacy of PAE across different patient subpopulations where formal guidance for PAE is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Three hundred two patients with BPH underwent PAE. Key baseline characteristics were gathered. Patients were compared from baseline to follow-ups with regards to (1) objective parameters, including maximum urinary flow rate (Q\n                      <jats:sub>max<\/jats:sub>\n                      ), post-void residual (PVR), and prostate specific antigen (PSA); (2) prostate volume; (3) BPH symptoms, including International Prostate Symptom Score (IPSS), IPSS Quality-of-Life (IPSS-QoL), and BPH Impact Index (BPH-II); (4) sexual symptoms, including the International Index of Erectile function (IIEF) and Male Sexual Health Questionnaire for Ejaculatory Function Short Form (MSHQ-EjD-SF); and (5) AEs. Additional sub-analyses were performed comparing the safety\/efficacy of PAE across key sub-groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PAE afforded significant improvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) in each subjective\/objective BPH parameter and sexual function score at nearly all follow-up points. Specifically, IPSS improved by 12.3\u201313.8 points (52.8\u201359.2%); IPSS-QoL by 2.3\u20132.8 points (47.9\u201358.3%); IIEF by 3.2\u20135.7 points (15.6\u201327.8%); PSA by 1.5\u20132.0\u00a0ng\/mL (15.6\u201328.5%); and prostate volume by 16.9%. Twelve (4.0%) AEs were reported; no sexual\/severe AEs were observed. PAE was safe and afforded significant improvement in subjective\/objective BPH parameters in patients with: prostate volumes\u2009\u2265\u200980\u00a0mL; prior BPH surgery\/intervention; higher medical comorbidity; pre-procedural catheter-dependent urinary retention; pre-procedural renal insufficiency; and pre-procedural hematuria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PAE improved subjective\/objective BPH parameters and sexual function. Further, it safely afforded significant improvement in subjective\/objective BPH parameters in specific contexts\/scenarios where current guidance for PAE is limited, including patients with larger prostates, prior BPH intervention, higher medical comorbidity, urinary retention, renal insufficiency, and hematuria. Altogether, PAE can be performed safely and effectively in several real-world contexts in which formal guidance for PAE is limited, and where it may offer unique advantages compared to surgical therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinicaltrials.gov, NCT03052049. Registered 6 September 2017,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03052049\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT03052049<\/jats:ext-link>\n                      ; Clinicaltrials.gov, NCT02026908. Registered 10 June 2019,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/cdn.clinicaltrials.gov\/large-docs\/08\/NCT02026908\/Prot_SAP_000.pdf\" ext-link-type=\"uri\">https:\/\/cdn.clinicaltrials.gov\/large-docs\/08\/NCT02026908\/Prot_SAP_000.pdf<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42155-026-00703-w","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:11:05Z","timestamp":1792735865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Who should be considered for prostate artery embolization: revisiting the urologic guidelines based on results from over 300 patients with benign prostatic hyperplasia"],"prefix":"10.1186","volume":"9","author":[{"given":"Gabriel M.","family":"Knight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Varadhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana","family":"Benishay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delmarie M.","family":"Rivera-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Hohlastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-4232","authenticated-orcid":false,"given":"Samdeep","family":"Mouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"703_CR1","doi-asserted-by":"publisher","first-page":"k2338","DOI":"10.1136\/bmj.k2338","volume":"361","author":"D Abt","year":"2018","unstructured":"Abt D, Hechelhammer L, M\u00fcllhaupt G, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018;361:k2338.","journal-title":"BMJ"},{"issue":"3","key":"703_CR2","doi-asserted-by":"publisher","first-page":"e13454","DOI":"10.1111\/ijcp.13454","volume":"74","author":"SF Al Rawashdah","year":"2020","unstructured":"Al Rawashdah SF, Pastore AL, Velotti G, et al. Sexual and functional outcomes of prostate artery embolisation: a prospective long-term follow-up, large cohort study. Int J Clin Pract. 2020;74(3):e13454.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"703_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jvir.2022.10.011","volume":"34","author":"MO Baerlocher","year":"2023","unstructured":"Baerlocher MO, Nikolic B, Sze DY. Adverse event classification: clarification and validation of the Society of Interventional Radiology specialty\u2013specific system. J Vasc Interv Radiol. 2023;34(1):1\u20133.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"703_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41443-020-00366-8","volume":"34","author":"C Bebi","year":"2022","unstructured":"Bebi C, Turetti M, Lievore E, et al. Sexual and ejaculatory function after holmium laser enucleation of the prostate and bipolar transurethral enucleation of the prostate: a single-center experience. Int J Impot Res. 2022;34(1):71\u201380.","journal-title":"Int J Impot Res"},{"issue":"4","key":"703_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jsxm.2022.01.006","volume":"19","author":"S Bhatia","year":"2022","unstructured":"Bhatia S, Acharya V, Jalaeian H, et al. Effect of prostate artery embolization on erectile function\u2014a single center experience of 167 patients. J Sex Med. 2022;19(4):594\u2013602.","journal-title":"J Sex Med"},{"issue":"3","key":"703_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jvir.2024.11.002","volume":"36","author":"S Bhatia","year":"2025","unstructured":"Bhatia S, Bhatia A, Richardson AJ, et al. Prostatic artery embolization: mid- to long-term outcomes in 1,075 patients. J Vasc Interv Radiol. 2025;36(3):456\u201366.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"703_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jvir.2017.08.022","volume":"29","author":"S Bhatia","year":"2018","unstructured":"Bhatia S, Sinha VK, Kava BR, et al. Efficacy of prostatic artery embolization for catheter-dependent patients with large prostate sizes and high comorbidity scores. J Vasc Interv Radiol. 2018;29(1):78-84.e71.","journal-title":"J Vasc Interv Radiol"},{"issue":"9","key":"703_CR8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00270-022-03199-8","volume":"45","author":"T Bilhim","year":"2022","unstructured":"Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E. Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Intervent Radiol. 2022;45(9):1324\u201336.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"703_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8\u201335.","journal-title":"Psychother Psychosom"},{"issue":"10","key":"703_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.5489\/cuaj.8334","volume":"17","author":"NS Dean","year":"2023","unstructured":"Dean NS, Assmus MA, Lee MS, Guo JN, Krambeck AE. Benign prostatic hyperplasia surgical re-treatment after prostatic urethral lift a narrative review. Can Urol Assoc J. 2023;17(10):353\u20139.","journal-title":"Can Urol Assoc J"},{"issue":"9","key":"703_CR11","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s00345-022-04098-w","volume":"40","author":"AM Durant","year":"2022","unstructured":"Durant AM, Moore J, Voleti S, et al. Salvage versus primary holmium laser enucleation of the prostate: trends, outcomes and safety analysis. World J Urol. 2022;40(9):2305\u201312.","journal-title":"World J Urol"},{"issue":"3","key":"703_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/JU.0000000000000319","volume":"202","author":"HE Foster","year":"2019","unstructured":"Foster HE, Dahm P, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. J Urol. 2019;202(3):592\u20138.","journal-title":"J Urol"},{"issue":"6","key":"703_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1055\/s-0042-1759701","volume":"39","author":"P Goyal","year":"2022","unstructured":"Goyal P, Salem R, Mouli SK. Controversies in prostate artery embolization: future best practice. Semin Intervent Radiol. 2022;39(6):562\u201370.","journal-title":"Semin Intervent Radiol"},{"issue":"5","key":"703_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jvir.2024.01.026","volume":"35","author":"P Goyal","year":"2024","unstructured":"Goyal P, Varadhan AK, Jenkins K, Hohlastos E, Salem R, Mouli SK. Prostatic artery embolization in patients with refractory lower urinary tract symptoms after a prior minimally invasive surgical treatment. J Vasc Interv Radiol. 2024;35(5):744\u201350.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"703_CR15","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jvir.2019.12.810","volume":"31","author":"I Insausti","year":"2020","unstructured":"Insausti I, S\u00e1ez de Oc\u00e1riz A, Galbete A, et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2020;31(6):882\u201390.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"703_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bju.16131","volume":"133","author":"P Kallidonis","year":"2024","unstructured":"Kallidonis P, Spinos T, Peteinaris A, Somani B, Liatsikos E. Salvage holmium laser enucleation of the prostate after previous interventions: a systematic review. BJU Int. 2024;133(2):141\u201351.","journal-title":"BJU Int"},{"issue":"6","key":"703_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00595-015-1236-x","volume":"46","author":"H Katayama","year":"2016","unstructured":"Katayama H, Kurokawa Y, Nakamura K, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46(6):668\u201385.","journal-title":"Surg Today"},{"issue":"3","key":"703_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.5395\/rde.2014.39.3.235","volume":"39","author":"HY Kim","year":"2014","unstructured":"Kim HY. Statistical notes for clinical researchers: Nonparametric statistical methods: 1. Nonparametric methods for comparing two groups. Restor Dent Endod. 2014;39(3):235\u20139.","journal-title":"Restor Dent Endod"},{"issue":"2","key":"703_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5395\/rde.2017.42.2.152","volume":"42","author":"HY Kim","year":"2017","unstructured":"Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher\u2019s exact test. Restor Dent Endod. 2017;42(2):152\u20135.","journal-title":"Restor Dent Endod"},{"key":"703_CR20","doi-asserted-by":"crossref","unstructured":"Knight GM, Talwar A, Salem R, Mouli S. Systematic review and meta-analysis comparing prostatic artery embolization to gold-standard transurethral resection of the prostate for benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2021;44(1):183\u201393.","DOI":"10.1007\/s00270-020-02657-5"},{"issue":"Suppl 7(Suppl 7","key":"703_CR21","first-page":"S3","volume":"7","author":"H Lepor","year":"2005","unstructured":"Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol. 2005;7(Suppl 7(Suppl 7)):S3-s11.","journal-title":"Rev Urol"},{"issue":"8","key":"703_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1756287217717889","volume":"9","author":"D Maclean","year":"2017","unstructured":"Maclean D, Maher B, Modi S, et al. Prostate artery embolization: a new, minimally invasive treatment for lower urinary tract symptoms secondary to prostate enlargement. Ther Adv Urol. 2017;9(8):209\u201316.","journal-title":"Ther Adv Urol"},{"issue":"6","key":"703_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.diii.2023.01.012","volume":"104","author":"A Marchi","year":"2023","unstructured":"Marchi A, Pellerin O, Querub C, et al. Long-term outcomes of prostate artery embolization for acute urinary retention: an analysis of 88 patients. Diagn Interv Imaging. 2023;104(6):292\u20136.","journal-title":"Diagn Interv Imaging"},{"issue":"2","key":"703_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1055\/s-0039-1688431","volume":"36","author":"S Mouli","year":"2019","unstructured":"Mouli S, Hohlastos E, Salem R. Prostate artery embolization. Semin Intervent Radiol. 2019;36(2):142\u20138.","journal-title":"Semin Intervent Radiol"},{"issue":"1","key":"703_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/JU.0000000000003976","volume":"212","author":"S Mouli","year":"2024","unstructured":"Mouli S, Salem R, McClure TD. Prostate artery embolization for benign prostatic hyperplasia. J Urol. 2024;212(1):216\u20139.","journal-title":"J Urol"},{"key":"703_CR26","doi-asserted-by":"crossref","unstructured":"Pisco JM, Bilhim T, Costa NV, et al. Randomised clinical trial of prostatic artery embolisation versus a sham procedure for benign prostatic hyperplasia. Eur Urol. 2020;77(3):354\u201362.","DOI":"10.1016\/j.eururo.2019.11.010"},{"issue":"8","key":"703_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.jvir.2016.04.001","volume":"27","author":"JM Pisco","year":"2016","unstructured":"Pisco JM, Bilhim T, Pinheiro LC, et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol. 2016;27(8):1115\u201322.","journal-title":"J Vasc Interv Radiol"},{"issue":"9","key":"703_CR28","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00330-012-2714-9","volume":"23","author":"JM Pisco","year":"2013","unstructured":"Pisco JM, Rio Tinto H, Campos Pinheiro L, et al. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol. 2013;23(9):2561\u201372.","journal-title":"Eur Radiol"},{"issue":"2","key":"703_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bju.14249","volume":"122","author":"AF Ray","year":"2018","unstructured":"Ray AF, Powell J, Speakman MJ, et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int. 2018;122(2):270\u201382.","journal-title":"BJU Int"},{"issue":"4","key":"703_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/21681805.2019.1623312","volume":"53","author":"E Sagen","year":"2019","unstructured":"Sagen E, Namnuan RO, Hedelin H, Nelz\u00e9n O, Peeker R. The morbidity associated with a TURP procedure in routine clinical practice, as graded by the modified Clavien-Dindo system. Scand J Urol. 2019;53(4):240\u20135.","journal-title":"Scand J Urol"},{"issue":"4","key":"703_CR31","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/01.ju.0000152318.79184.6f","volume":"173","author":"CS Saigal","year":"2005","unstructured":"Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol. 2005;173(4):1309\u201313.","journal-title":"J Urol"},{"key":"703_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.urology.2018.07.012","volume":"120","author":"R Salem","year":"2018","unstructured":"Salem R, Hairston J, Hohlastos E, et al. Prostate artery embolization for lower urinary tract symptoms secondary to benign prostatic hyperplasia: results from a prospective FDA-approved investigational device exemption study. Urology. 2018;120:205\u201310.","journal-title":"Urology"},{"key":"703_CR33","doi-asserted-by":"publisher","unstructured":"Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline 2026. Part III: procedural\/surgical management. J Urol. 2026. https:\/\/doi.org\/10.1097\/JU.0000000000005099.","DOI":"10.1097\/JU.0000000000005099"},{"key":"703_CR34","doi-asserted-by":"publisher","first-page":"100672","DOI":"10.1016\/j.lanepe.2023.100672","volume":"31","author":"M Sapoval","year":"2023","unstructured":"Sapoval M, Thiounn N, Descazeaud A, et al. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): A randomised, multicentre, open-label, phase 3, superiority trial. Lancet Reg Health Eur. 2023;31:100672.","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"703_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4103\/0970-1591.127856","volume":"30","author":"MJ Speakman","year":"2014","unstructured":"Speakman MJ, Cheng X. Management of the complications of BPH\/BOO. Indian J Urol. 2014;30(2):208\u201313.","journal-title":"Indian J Urol"},{"key":"703_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15010023","author":"F Zorzi","year":"2025","unstructured":"Zorzi F, Rossin G, Digregorio M, et al. Prostatic artery embolization in elderly comorbid patients with benign prostatic hyperplasia: Safety, efficacy, and predictive factors of clinical failure. J Pers Med. 2025. https:\/\/doi.org\/10.3390\/jpm15010023.","journal-title":"J Pers Med"}],"container-title":["CVIR Endovascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-026-00703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42155-026-00703-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-026-00703-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:01:40Z","timestamp":1792782100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42155-026-00703-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1186\/s42155-026-00703-w","relation":{},"ISSN":["2520-8934"],"issn-type":[{"value":"2520-8934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The need for approval was waived.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"135"}}